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To the Editor,
Jialal and Pahwa note the importance of daratumumab 
interference with monoclonal protein quantitation in multi-
ple myeloma [1]. We agree that daratumumab may interfere 
with monoclonal protein quantitation. While the focus of 
our manuscript was to describe a method to reduce the risk 
of inaccurate response classification [i.e. very good partial 
response (VGPR) vs. complete response (CR)] [2], inaccurate 
quantitation due to positive interference by daratumumab 
could give the impression of resistance to therapy.
One point of clarification is that the clinical conse-
quences of the described bias are difficult to estimate. 
Statistical significance aside, the effect size of the bias 
appears to be largely below the reference change value 
(RCV) as determined from biological variation and impre-
cision data for monoclonal proteins [3, 4]. The estimated 
RCV for monoclonal proteins ranges from 27% to 56%. The 
reported median bias of 10% and the maximum observed 
bias of approximately 32% are thus largely within the 
combined biological variation and noise of monoclonal 
protein quantitation by serum protein electrophoresis 
(SPE; scanning densitometry). In the same line, impreci-
sion of the SPE method may explain the reported inter-
ference of M-protein concentration in patients in which 
the M-protein does not co-migrate with daratumumab. 
Daratumumab consistently migrates as a sharp band at 
the same electrophoretic location, and interference on 
quantification with nonoverlapping M-proteins is there-
fore not expected. Further, it is unlikely that the daratu-
mumab treatment course would change as a result of a  ≤ 1 
g/L positive bias; the maximum mean (± standard devia-
tion) reported maximum concentration for daratumumab 
at the end of the initial weekly dosing schedule at a dose 
of 16 mg/kg is 915 (410) μg/mL [5]. We agree that further 
studies aimed at determining if there is a clinical impact 
are warranted.
With respect to the daratumumab immunofixation 
reflex assay (DIRA), this method is not intended to address 
the issue of quantitation, but rather to determine if the 
patient has achieved immunofixation-negative serologic 
CR or not. We only recommend selective use to differenti-
ate response classification for several reasons: (1) there is 
a lack of available antisera available to most laboratories; 
(2) as Jialal and Pahwa state, there is an added expense 
and complexity in immunofixation interpretation; and (3) 
laboratories running SPE typically do not know if daratu-
mumab is present in most routinely obtained SPE samples. 
Thus, DIRA is recommended in selected cases using expe-
rienced interpreters, where it is essential to accurately 
differentiate VGPR versus CR, for example, as part of a 
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clinical trial. In the future, use of a DIRA-like assay during 
routine patient management may become more wide-
spread if a commercial version becomes available.
Overall, the issue of quantitative interference may be 
ameliorated by avoiding collection of samples immediately 
after treatment with daratumumab or any other monoclonal 
therapy [6]. The utility of serum free light chains as an unaf-
fected metric of treatment response is well justified [7]. The 
authors can confirm that serum free light-chain assays are 
also unaffected by rituximab, trastuzumab, bevacizumab, 
infliximab, cetuximab, adalimumab, natalizumab, and sil-
tuximab (McCudden, C, et al; unpublished data). As such, 
serum free light-chain (sFLC) analysis seems indeed a good 
alternative for patients with light-chain multiple myeloma; 
however, serum immunofixation electrophoresis monitor-
ing is more sensitive than sFLC analysis in patients with 
an intact M-protein [8]. More over, one parameter cannot 
replace the other to assess therapy response. For a patient 
with an intact M-protein to be classified as having a strin-
gent complete remission, as defined by the International 
Myeloma Working Group, the serum must be negative as 
determined by IFE, along with a normal sFLC ratio [9].
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